New ulcerative colitis drug takes first step in human testing
NCT ID NCT06681181
First seen Oct 31, 2025 · Last updated May 14, 2026 · Updated 21 times
Summary
This study is the first time GSK4528287, a drug for inflammatory bowel diseases like ulcerative colitis, is being given to humans. It involves 48 healthy volunteers who receive a single dose to check for side effects, measure drug levels in the blood, and see how the drug works in the body. The dose is increased gradually in different groups to find a safe range.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLITIS, ULCERATIVE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Cambridge, CB2 0GG, United Kingdom
Conditions
Explore the condition pages connected to this study.